The Keynote-012 trial (NCT01848834), led by Seiwert et al. [30] investigated pembrolizumab in 60 patients with PD-L1-positive recurrent or metastatic HNSCC, including two with laryngeal cancer. The gene discussed is CD274; the disease is laryngeal carcinoma.